Major Depressive Disorder
Conditions
Brief summary
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
Interventions
DRUGSPD489 (Lisdexamfetamine dimesylate )
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
DRUGPlacebo
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Sponsors
Shire
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subject is able to provide written, personally signed, and dated informed consent to participate in the study. * Subject is between 18 and 65 years of age. * Subject has a primary diagnosis of non-psychotic MDD (single or recurrent). * Subject has a MADRS total score 24. * Subject who is female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test at the and agrees to comply with any applicable contraceptive requirements of the protocol. * Subject is able to swallow a capsule.
Exclusion criteria
* Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents. * Subject who has a lifetime history of treatment resistant depression. * Subject has a current co-morbid psychiatric disorder. Excluded are: any significant Axis II disorder (including borderline personality disorder), any bipolar disorder, any current or lifetime psychosis, post traumatic stress disorder, obsessive compulsive disorder, any pervasive development disorder, anorexia nervosa and bulimia nervosa. * Subject has been hospitalized (within the last 12 months) for their current MDD episode. * Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD). * Subject has a first degree relative that has been diagnosed with bipolar I disorder. * Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder * Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation. * Subject has a concurrent chronic or acute illness or unstable medical condition. * Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions. * Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. * Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit. * Subject has a known family history of sudden cardiac death or ventricular arrhythmia. * Subject has glaucoma. * Subject has a history of moderate to severe hypertension. * Current use of any other medications (including over-the-counter \[OTC\], herbal or homeopathic preparations) that have central nervous system effects. * Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior. * The subject has a known or suspected intolerance, hypersensitivity, or contraindications to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl). * Subject has a positive urine drug result. * Subject has a body mass index (BMI) of \<18.5 or \>40. * Subject is female and is pregnant or nursing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks | 8 weeks | MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving a 25% Response on the MADRS | up to 8 weeks | The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET). |
| Percentage of Participants Achieving a 50% Response on the MADRS | up to 8 weeks | The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET). |
| Percentage of Participants Achieving Remission on the MADRS | up to 8 weeks | MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET). |
| Mean Change From Baseline Over Time in MADRS Total Score | Baseline and up to 8 weeks | MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. |
| Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR) | up to 8 weeks | The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \[low amount of symptom\]) to 3 (representing the least favorable response \[frequent/intense symptom\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms. |
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks | 8 weeks | Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. |
| Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF) | up to 8 weeks | The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life. |
| Clinical Global Impressions - Global Improvement (CGI-I) | up to 8 weeks | Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. |
| Columbia Suicide Severity Rating Scale (C-SSRS) | up to 8 weeks | C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale. |
| Amphetamine Cessation Symptom Assessment (ACSA) | up to 8 weeks | ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity. |
| Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2) | up to 8 weeks | Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life. |
Countries
Canada, Croatia, Mexico, Puerto Rico, Spain, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Antidepressant + Double-blind Placebo Oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily, double-blind placebo (matching SPD489) for 8 weeks. | 201 |
| Antidepressant + Double-blind SPD489 Oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily SPD489 (Lisdexamfetamine dimesylate optimized among 20, 30, 50, or 70 mg dose) for 8 weeks. | 201 |
| Total | 402 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Antidepressant Lead-in Phase | Adverse Event | 39 | 0 | 0 |
| Antidepressant Lead-in Phase | Lost to Follow-up | 96 | 0 | 0 |
| Antidepressant Lead-in Phase | Met BP Or Pulse Withdrawal Criteria | 22 | 0 | 0 |
| Antidepressant Lead-in Phase | Other | 119 | 0 | 0 |
| Antidepressant Lead-in Phase | Protocol Violation | 29 | 0 | 0 |
| Antidepressant Lead-in Phase | Withdrawal by Subject | 61 | 0 | 0 |
| Randomized Phase | Adverse Event | 9 | 10 | 11 |
| Randomized Phase | Lack of Efficacy | 0 | 0 | 1 |
| Randomized Phase | Lost to Follow-up | 34 | 5 | 6 |
| Randomized Phase | Met BP Or Pulse Withdrawal Criteria | 2 | 3 | 3 |
| Randomized Phase | Other | 12 | 5 | 11 |
| Randomized Phase | Protocol Violation | 4 | 5 | 0 |
| Randomized Phase | Withdrawal by Subject | 16 | 10 | 10 |
Baseline characteristics
| Characteristic | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 | Total |
|---|---|---|---|
| Age, Continuous | 41.8 Years STANDARD_DEVIATION 12.04 | 42.2 Years STANDARD_DEVIATION 12.32 | 42 Years STANDARD_DEVIATION 12.17 |
| Age, Customized 18-55 years | 173 Participants | 170 Participants | 343 Participants |
| Age, Customized 56-65 years | 28 Participants | 31 Participants | 59 Participants |
| Sex: Female, Male Female | 133 Participants | 129 Participants | 262 Participants |
| Sex: Female, Male Male | 68 Participants | 72 Participants | 140 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 54 / 201 | 70 / 201 |
| serious Total, serious adverse events | 5 / 201 | 3 / 201 |
Outcome results
Primary
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Antidepressant + Placebo | Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks | -6.3 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks | -6.1 units on a scale |
p-value: 0.88395% CI: [-1.7, 2]Mixed- effects Model for Repeat Measures
Secondary
Amphetamine Cessation Symptom Assessment (ACSA)
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Antidepressant + Placebo | Amphetamine Cessation Symptom Assessment (ACSA) | 15.1 units on a scale | Standard Deviation 10.71 |
| Antidepressant + SPD489 | Amphetamine Cessation Symptom Assessment (ACSA) | 14.7 units on a scale | Standard Deviation 10.94 |
Secondary
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
Time frame: 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Antidepressant + Placebo | Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks | -4.3 units on a scale |
| Antidepressant + SPD489 | Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks | -4.7 units on a scale |
p-value: 0.57695% CI: [-1.8, 1]Mixed- effects Model for Repeat Measures
Secondary
Clinical Global Impressions - Global Improvement (CGI-I)
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Antidepressant + Placebo | Clinical Global Impressions - Global Improvement (CGI-I) | Improved | 53.3 percentage of participants |
| Antidepressant + Placebo | Clinical Global Impressions - Global Improvement (CGI-I) | Not Improved | 46.2 percentage of participants |
| Antidepressant + Placebo | Clinical Global Impressions - Global Improvement (CGI-I) | Not Assessed | 0.5 percentage of participants |
| Antidepressant + SPD489 | Clinical Global Impressions - Global Improvement (CGI-I) | Improved | 55.3 percentage of participants |
| Antidepressant + SPD489 | Clinical Global Impressions - Global Improvement (CGI-I) | Not Improved | 44.7 percentage of participants |
| Antidepressant + SPD489 | Clinical Global Impressions - Global Improvement (CGI-I) | Not Assessed | 0 percentage of participants |
Secondary
Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Antidepressant + Placebo | Columbia Suicide Severity Rating Scale (C-SSRS) | ≥1 postive suicidal ideation | 7.0 percentage of participants |
| Antidepressant + Placebo | Columbia Suicide Severity Rating Scale (C-SSRS) | ≥1 suicidal attempt | 0.5 percentage of participants |
| Antidepressant + SPD489 | Columbia Suicide Severity Rating Scale (C-SSRS) | ≥1 suicidal attempt | 0 percentage of participants |
| Antidepressant + SPD489 | Columbia Suicide Severity Rating Scale (C-SSRS) | ≥1 postive suicidal ideation | 7.0 percentage of participants |
Secondary
Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)
The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Antidepressant + Placebo | Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF) | 7.2 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF) | 7.0 units on a scale |
Secondary
Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)
The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \[low amount of symptom\]) to 3 (representing the least favorable response \[frequent/intense symptom\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Antidepressant + Placebo | Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR) | -2.6 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR) | -2.3 units on a scale |
Secondary
Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)
Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Antidepressant + Placebo | Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2) | Physical | 0.69 units on a scale |
| Antidepressant + Placebo | Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2) | Mental | 5.59 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2) | Mental | 6.5 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2) | Physical | -0.81 units on a scale |
Secondary
Mean Change From Baseline Over Time in MADRS Total Score
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: Baseline and up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Antidepressant + Placebo | Mean Change From Baseline Over Time in MADRS Total Score | Visit 9 (Week 9) | -2.2 units on a scale |
| Antidepressant + Placebo | Mean Change From Baseline Over Time in MADRS Total Score | Visit 12 (Week 12) | -6.2 units on a scale |
| Antidepressant + Placebo | Mean Change From Baseline Over Time in MADRS Total Score | Visit 13 (Week 14) | -7.4 units on a scale |
| Antidepressant + Placebo | Mean Change From Baseline Over Time in MADRS Total Score | Visit 10 (Week 10) | -3.8 units on a scale |
| Antidepressant + Placebo | Mean Change From Baseline Over Time in MADRS Total Score | Visit 14 (Week 16) | -6.3 units on a scale |
| Antidepressant + Placebo | Mean Change From Baseline Over Time in MADRS Total Score | Visit 11 (Week 11) | -6.0 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline Over Time in MADRS Total Score | Visit 14 (Week 16) | -6.1 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline Over Time in MADRS Total Score | Visit 11 (Week 11) | -5.4 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline Over Time in MADRS Total Score | Visit 9 (Week 9) | -3.4 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline Over Time in MADRS Total Score | Visit 10 (Week 10) | -4.2 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline Over Time in MADRS Total Score | Visit 12 (Week 12) | -5.6 units on a scale |
| Antidepressant + SPD489 | Mean Change From Baseline Over Time in MADRS Total Score | Visit 13 (Week 14) | -7.3 units on a scale |
Secondary
Percentage of Participants Achieving a 25% Response on the MADRS
The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Antidepressant + Placebo | Percentage of Participants Achieving a 25% Response on the MADRS | 65.0 percentage of participants |
| Antidepressant + SPD489 | Percentage of Participants Achieving a 25% Response on the MADRS | 74.5 percentage of participants |
Secondary
Percentage of Participants Achieving a 50% Response on the MADRS
The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Antidepressant + Placebo | Percentage of Participants Achieving a 50% Response on the MADRS | 38.5 percentage of participants |
| Antidepressant + SPD489 | Percentage of Participants Achieving a 50% Response on the MADRS | 41.0 percentage of participants |
Secondary
Percentage of Participants Achieving Remission on the MADRS
MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).
Time frame: up to 8 weeks
Population: Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Antidepressant + Placebo | Percentage of Participants Achieving Remission on the MADRS | 22.5 percentage of participants |
| Antidepressant + SPD489 | Percentage of Participants Achieving Remission on the MADRS | 18.5 percentage of participants |